Treatment preference for once-weekly versus once-daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Xie X, Chen Y, Wang P, Hu M.
europepmc +1 more source
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim +5 more
wiley +1 more source
Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion. [PDF]
Hamamoto Y, Usui R.
europepmc +1 more source
The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski +7 more
wiley +1 more source
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan +5 more
wiley +1 more source
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors. [PDF]
Bosi A +7 more
europepmc +1 more source
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano +4 more
wiley +1 more source
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. [PDF]
He L, Li J, Cheng X, Luo L, Huang Y.
europepmc +1 more source
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh +2 more
wiley +1 more source
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications. [PDF]
Kuthati Y, Davuluri VNG, Wong CS.
europepmc +1 more source

